Interplay between enterobactin, myeloperoxidase and lipocalin 2 regulates E. Coli survival in the inflamed gut

Nature Communications

Volumn 6, Issue , 2015, Pages

  Singh, Vishal ^a   Yeoh, Beng San ^a   Xiao, Xia ^a   Kumar, Manish ^a   Bachman, Michael ^b   Borregaard, Niels ^c   Joe, Bina ^d   Vijay Kumar, Matam ^a,e  

^a PENNSYLVANIA STATE UNIVERSITY   (United States)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^c Rigshospitalet   (Denmark)

^d MEDICAL COLLEGE OF OHIO   (United States)

^e PENN STATE MILTON S HERSHEY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ENTEROCHELIN; FERRIC ION; MYELOPEROXIDASE; NEUTROPHIL GELATINASE ASSOCIATED LIPOCALIN; SALMOCHELIN; UNCLASSIFIED DRUG; YERSINIABACTIN; ACUTE PHASE PROTEIN; DEXTRAN SULFATE; LCN2 PROTEIN, HUMAN; LCN2 PROTEIN, MOUSE; LIPOCALIN; ONCOPROTEIN; PEROXIDASE;

COMMENSAL; ENZYME ACTIVITY; FECAL COLIFORM; IMMUNE RESPONSE; INHIBITION; PROTEIN; SIDEROPHORE; SURVIVAL;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BACTERIAL SURVIVAL; COLITIS; ENTERITIS; ENZYME ACTIVITY; ENZYME INHIBITION; ESCHERICHIA COLI; GASTROENTERITIS; INNATE IMMUNITY; MOUSE; NONHUMAN; SPECTROSCOPY; ANIMAL; ANTAGONISTS AND INHIBITORS; BAGG ALBINO MOUSE; CHEMICALLY INDUCED; FEMALE; GENE EXPRESSION REGULATION; GENETICS; INFLAMMATION; METABOLISM; MICROBIOLOGY; PHYSIOLOGY;

ACUTE-PHASE PROTEINS; ANIMALS; COLITIS; DEXTRAN SULFATE; ENTEROBACTIN; ESCHERICHIA COLI; FEMALE; GENE EXPRESSION REGULATION; INFLAMMATION; LIPOCALIN-2; LIPOCALINS; MICE, INBRED BALB C; ONCOGENE PROTEINS; PEROXIDASE; PROTO-ONCOGENE PROTEINS;

EID: 84929223565     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/ncomms8113     Document Type: Article

References (61)

1. Goetz, D. H. et al. The neutrophil lipocalin NGAL is a bacteriostatic agent that interferes with siderophore-mediated iron acquisition. Mol. Cell 10, 1033-1043 (2002).
2. Nairz, M., Schroll, A., Sonnweber, T. & Weiss, G. The struggle for iron-a metal at the host-pathogen interface. Cell Microbiol. 12, 1691-1702 (2010).
3. Skaar, E. P. The battle for iron between bacterial pathogens and their vertebrate hosts. PLoS Pathog. 6, e1000949 (2010).
4. Lin, H., Fischbach, M. A., Liu, D. R. & Walsh, C. T. In vitro characterization of salmochelin and enterobactin trilactone hydrolases IroD, IroE, and Fes. J. Am. Chem. Soc. 127, 11075-11084 (2005).
5. Bellaire, B. H., Elzer, P. H., Baldwin, C. L. & Roop, 2nd R. M. Production of the siderophore 2, 3-dihydroxybenzoic acid is required for wild-type growth of Brucella abortus in the presence of erythritol under low-iron conditions in vitro. Infect. Immun. 71, 2927-2832 (2003).
6. Williams, P. H. Novel iron uptake system specified by ColV plasmids: an important component in the virulence of invasive strains of Escherichia coli. Infect. Immun. 26, 925-932 (1979).
7. Lawlor, M. S., O'Connor, C. & Miller, V. L. Yersiniabactin is a virulence factor for Klebsiella pneumoniae during pulmonary infection. Infect. Immun. 75, 1463-1472 (2007).
8. Ratledge, C. & Dover, L. G. Iron metabolism in pathogenic bacteria. Annu. Rev. Microbiol. 54, 881-941 (2000).
9. Cusumano, C. K., Hung, C. S., Chen, S. L. & Hultgren, S. J. Virulence plasmid harbored by uropathogenic Escherichia coli functions in acute stages of pathogenesis. Infect. Immun. 78, 1457-1467 (2010).
10. Klebanoff, S. J., Kettle, A. J., Rosen, H., Winterbourn, C. C. & Nauseef, W. M. Myeloperoxidase: a front-line defender against phagocytosed microorganisms. J. Leukoc. Biol. 93, 185-198 (2013).
11. Sharma, S. et al. Lactoperoxidase: structural insights into the function, ligand binding and inhibition. Int. J. Biochem. Mol. Biol. 4, 108-128 (2013).
12. Chakraborty, S., Kaur, S., Guha, S. & Batra, S. K. The multifaceted roles of neutrophil gelatinase associated lipocalin (NGAL) in inflammation and cancer. Biochim. Biophys. Acta 1826, 129-169 (2012).
13. Vujkovic-Cvijin, I. et al. Dysbiosis of the gut microbiota is associated with hiv disease progression and tryptophan catabolism. Sci. Transl. Med. 5, 193ra191 (2013).
14. Normann, E., Fahlen, A., Engstrand, L. & Lilja, H. E. Intestinal microbial profiles in extremely preterm infants with and without necrotizing enterocolitis. Acta Paediatr. 102, 129-136 (2013).
15. Baumgart, M. et al. Culture independent analysis of ileal mucosa reveals a selective increase in invasive Escherichia coli of novel phylogeny relative to depletion of Clostridiales in Crohn's disease involving the ileum. ISME J. 1, 403-418 (2007).
16. Carroll, I. M., Ringel-Kulka, T., Siddle, J. P. & Ringel, Y. Alterations in composition and diversity of the intestinal microbiota in patients with diarrheapredominant irritable bowel syndrome. Neurogastroenterol. Motil. 24, 521-530 e248 (2012).
17. Hildebrand, F. et al. Inflammation-associated enterotypes, host genotype, cage and inter-individual effects drive gut microbiota variation in common laboratory mice. Genome Biol. 14, R4 (2013).
18. Spees, A. M. et al. Streptomycin-induced inflammation enhances Escherichia coli gut colonization through nitrate respiration. mBio 4, e00430-13 (2013).
19. Lupp, C. et al. Host-mediated inflammation disrupts the intestinal microbiota and promotes the overgrowth of Enterobacteriaceae. Cell Host Microbe 2, 204 (2007).
20. Raetz, M. et al. Parasite-induced TH1 cells and intestinal dysbiosis cooperate in IFN-gamma-dependent elimination of Paneth cells. Nat. Immunol. 14, 136-142 (2013).
21. Winter, S. E. & Baumler, A. J. Why related bacterial species bloom simultaneously in the gut: principles underlying the 'Like will to like' concept. Cell Microbiol. 16, 179-184 (2013).
22. Winter, S. E., Lopez, C. A. & Baumler, A. J. The dynamics of gut-associated microbial communities during inflammation. EMBO Rep. 14, 319-327 (2013).
23. Winter, S. E. et al. Host-derived nitrate boosts growth of E. coli in the inflamed gut. Science 339, 708-711 (2013).
24. Kettle, A. J., Gedye, C. A. & Winterbourn, C. C. Mechanism of inactivation of myeloperoxidase by 4-aminobenzoic acid hydrazide. Biochem. J. 321, 503-508 (1997).
25. Nemeth, E. et al. IL-6 mediates hypoferremia of inflammation by inducing the synthesis of the iron regulatory hormone hepcidin. J. Clin. Invest. 113, 1271-1276 (2004).
26. Darfeuille-Michaud, A. et al. Presence of adherent Escherichia coli strains in ileal mucosa of patients with Crohn's disease. Gastroenterology 115, 1405-1413 (1998).
27. Vijay-Kumar, M. et al. Flagellin suppresses epithelial apoptosis and limits disease during enteric infection. Am. J. Pathol. 169, 1686-1700 (2006).
28. Vijay-Kumar, M. et al. Toll-like receptor 5-deficient mice have dysregulated intestinal gene expression and nonspecific resistance to Salmonella-induced typhoid-like disease. Infect. Immun. 76, 1276-1281 (2008).
29. Cowland, J. B., Sorensen, O. E., Sehested, M. & Borregaard, N. Neutrophil gelatinase-associated lipocalin is up-regulated in human epithelial cells by IL-1 beta, but not by TNF-alpha. J. Immunol. 171, 6630-6639 (2003).
30. Vijay-Kumar, M. et al. Protein kinase R mediates intestinal epithelial gene remodeling in response to double-stranded RNA and live rotavirus. J. Immunol. 174, 6322-6331 (2005).
31. Willing, B. et al. Twin studies reveal specific imbalances in the mucosaassociated microbiota of patients with ileal Crohn's disease. Inflamm. Bowel Dis. 15, 653-660 (2009).
32. Reeder, B. J. & Wilson, M. T. Desferrioxamine inhibits production of cytotoxic heme to protein cross-linked myoglobin: a mechanism to protect against oxidative stress without iron chelation. Chem. Res. Toxicol. 18, 1004-1011 (2005).
33. Achard, M. E. et al. An antioxidant role for catecholate siderophores in Salmonella. Biochem. J. 454, 543-549 (2013).
34. Paauw, A., Leverstein-van Hall, M. A., van Kessel, K. P., Verhoef, J. & Fluit, A. C. Yersiniabactin reduces the respiratory oxidative stress response of innate immune cells. PLoS ONE 4, e8240 (2009).
35. Adler, C. et al. The alternative role of enterobactin as an oxidative stress protector allows Escherichia coli colony development. PLoS ONE 9, e84734 (2014).
36. Adler, C. et al. Catecholate siderophores protect bacteria from pyochelin toxicity. PLoS ONE 7, e46754 (2012).
37. Borregaard, N. & Cowland, J. B. Neutrophil gelatinase-associated lipocalin, a siderophore-binding eukaryotic protein. Biometals 19, 211-215 (2006).
38. Bachman, M. A., Miller, V. L. & Weiser, J. N. Mucosal lipocalin 2 has pro-inflammatory and iron-sequestering effects in response to bacterial enterobactin. PLoS Pathog. 5, e1000622 (2009).
39. Flo, T. H. et al. Lipocalin 2 mediates an innate immune response to bacterial infection by sequestrating iron. Nature 432, 917-921 (2004).
40. Berger, T. et al. Lipocalin 2-deficient mice exhibit increased sensitivity to Escherichia coli infection but not to ischemia-reperfusion injury. Proc. Natl Acad. Sci. USA. 103, 1834-1839 (2006).
41. Raffatellu, M. et al. Lipocalin-2 resistance confers an advantage to Salmonella enterica serotype Typhimurium for growth and survival in the inflamed intestine. Cell Host Microbe 5, 476-486 (2009).
42. Gisbert, J. P. & Gomollon, F. Common misconceptions in the diagnosis and management of anemia in inflammatory bowel disease. Am. J. Gastroenterol. 103, 1299-1307 (2008).
43. Ganz, T. & Nemeth, E. Hepcidin and iron homeostasis. Biochim. Biophys. Acta 1823, 1434-1443 (2012).
44. Faber, F. & Baumler, A. J. The impact of intestinal inflammation on the nutritional environment of the gut microbiota. Immunol. Lett. 162, 48-53 (2014).
45. Crouch, M. L., Castor, M., Karlinsey, J. E., Kalhorn, T. & Fang, F. C. Biosynthesis and IroC-dependent export of the siderophore salmochelin are essential for virulence of Salmonella enterica serovar Typhimurium. Mol. Microbiol. 67, 971-983 (2008).
46. Henderson, J. P. et al. Quantitative metabolomics reveals an epigenetic blueprint for iron acquisition in uropathogenic Escherichia coli. PLoS Pathog. 5, e1000305 (2009).
47. Fischbach, M. A., Lin, H., Liu, D. R. & Walsh, C. T. How pathogenic bacteria evade mammalian sabotage in the battle for iron. Nat. Chem. Biol. 2, 132-138 (2006).
48. Croxen, M. A. et al. Recent advances in understanding enteric pathogenic Escherichia coli. Clin. Microbiol. Rev. 26, 822-880 (2013).
49. Lambeth, J. D. NOX enzymes and the biology of reactive oxygen. Nat. Rev. Immunol. 4, 181-189 (2004).
50. Schutz, E. [The treatment of intestinal diseases with Mutaflor. A multicenter retrospective study]. Fortschr. Med. 107, 599-602 (1989).
51. Mollenbrink, M. & Bruckschen, E. [Treatment of chronic constipation with physiologic Escherichia coli bacteria. Results of a clinical study of the effectiveness and tolerance of microbiological therapy with the E. coli Nissle 1917 strain (Mutaflor)]. Med. Klin. 89, 587-593 (1994).
52. Sokolov, A. V. et al. Proatherogenic modification of LDL by surface-bound myeloperoxidase. Chem. Phys. Lipids 180, 72-80 (2014).
53. Heimesaat, M. M. et al. Colonization resistance against genetically modified Escherichia coli K12 (W3110) strains is abrogated following broad-spectrum antibiotic treatment and acute ileitis. Eur. J. Microbiol. Immunol. 3, 222-228 (2013).
54. Bereswill, S. et al. Pro-inflammatory potential of Escherichia coli strains K12 and Nissle 1917 in a murine model of acute ileitis. Eur. J. Microbiol. Immunol. 3, 126-134 (2013).
55. Capeillere-Blandin, C. Oxidation of guaiacol by myeloperoxidase: a two-electron-oxidized guaiacol transient species as a mediator of NADPH oxidation. Biochem. J. 336, 395-404 (1998).
56. Castaneda, F. E. et al. Targeted deletion of metalloproteinase 9 attenuates experimental colitis in mice: central role of epithelial-derived MMP. Gastroenterology 129, 1991-2008 (2005).
57. Schwyn, B. & Neilands, J. B. Universal chemical assay for the detection and determination of siderophores. Anal. Biochem. 160, 47-56 (1987).
58. Atosuo, J. T. & Lilius, E. M. The real-time-based assessment of the microbial killing by the antimicrobial compounds of neutrophils. ScientificWorldJournal 11, 2382-2390 (2011).
59. Chassaing, B., Aitken, J. D., Malleshappa, M. & Vijay-Kumar, M. Dextran sulfate sodium (DSS)-induced colitis in mice. Curr. Protoc. Immunol. 104, Unit 15 25 (2014; edited by John E. Coligan et al..
60. Graziano, J. H., Grady, R. W. & Cerami, A. The identification of 2, 3-dihydroxybenzoic acid as a potentially useful iron-chelating drug. J. Pharmacol. Exp. Ther. 190, 570-575 (1974).
61. Khanna, V. et al. Cholesterol diet withdrawal leads to an initial plaque instability and subsequent regression of accelerated iliac artery atherosclerosis in rabbits. PLoS ONE 8, e77037 (2013).